Trials / Recruiting
RecruitingNCT07075640
A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-Ascending Dose Safety, Tolerability, and Pharmacokinetic Study of AG-236 Administered as a Subcutaneous Dose in Healthy Male and Female Participants
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Agios Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The primary purpose of this study is to assess the safety and tolerability of a single dose of AG-236 administered subcutaneously in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AG-236 | Subcutaneous (SC) Injection |
| DRUG | Placebo | SC Injection |
Timeline
- Start date
- 2025-07-07
- Primary completion
- 2026-03-25
- Completion
- 2026-08-31
- First posted
- 2025-07-20
- Last updated
- 2026-03-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07075640. Inclusion in this directory is not an endorsement.